Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Insmed (INSM) Tops Q2 EPS by 5c, Revenues Beat
August 1, 2019 7:54 AM EDTInsmed (NASDAQ: INSM) reported Q2 EPS of ($0.81), $0.05 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $30 million versus the consensus estimate of $25.76 million.
Second Quarter 2019 Financial Results
Total revenue for the second quarter ended June 30, 2019 was $30.0 million, comprising U.S. net sales of $29.0 million and ex-U.S. net sales of $1.0 million. The ex-U.S. net product sales include $0.9 million from the Temporary Authorization for Use (Autorisation Temporaire d'Utilisation or ATU) program in France and $0.1 million from the named patient program in Germany, both compassionate use programs. Cost of product... More